Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery

Table 5

Univariate Cox regression analyses of risk factors associated with progression-free survival and overall survival after curative surgery for AFP-positive (≥20 ng/ml) hepatocellular carcinoma.

Variables	HR comparison	Progression-free survival		Overall survival
		UV HR (95% CI)	UV value	UV HR (95% CI)	UV value
Gender	Male vs. female	0.927 (0.479–1.793)	0.822	2.967 (0.684–12.878)	0.146
Age	≥60 vs.<60 years	0.823 (0.449–1.508)	0.529	0.775 (0.311–1.932)	0.585
HbsAg positivity	Yes vs. no	0.770 (0.302–1.962)	0.584	0.896 (0.208–3.859)	0.882
Liver cirrhosis	Yes vs. no	1.386 (0.743–2.587)	0.305	1.180 (0.450–3.096)	0.737
AST/ALT	≥1 vs. <1	0.980 (0.538–1.787)	0.948	1.029 (0.403–2.622)	0.953
GGT level	≥45 U/L vs. <45 U/L	2.122 (1.203–3.745)	0.009	1.974 (0.837–4.656)	0.120
CD3+ T cell ratio	≥77% vs. <77%	0.616 (0.275–1.380)	0.239	0.686 (0.201–2.345)	0.548
CD4+ T cell ratio	≥41.6% vs. <41.6%	1.215 (0.664–2.223)	0.528	0.200 (0.047–0.863)	0.031
CD8+ T cell ratio	≥29.6% vs. <29.6%	0.505 (0.261–0.975)	0.042	0.780 (0.310–1.964)	0.598
HLADR+ T cell ratio	≥5.8% vs. <5.8%	0.499 (0.278–0.895)	0.020	0.589 (0.244–1.421)	0.239
B cell ratio	≥18.2% vs. <18.2%	1.060 (0.569–1.977)	0.854	1.338 (0.551–3.249)	0.520
NK cell ratio	≥25.6% vs, <25.6%	1.680 (0.783–3.603)	0.183	2.816 (1.003–7.909)	0.049
Edmondson grade	III-IV vs. I-II	1.630 (0.908–2.926)	0.101	1.549 (0.648–3.702)	0.325
Largest tumor size	≥5 vs. <5 cm	1.467 (0.796–2.703)	0.219	2.438 (1.021–5.825)	0.045
Microvascular invasion	Yes vs. no	1.538 (0.868–2.729)	0.140	3.514 (1.404–8.797)	0.007
Capsular invasion	Yes vs. no	1.571 (0.888–2.778)	0.121	1.517 (0.625–3.685)	0.357

AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase.